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PEMENCILAN DAN PENGENALPASTIAN PENANDA KIMIA 
DARIPADA LABISIA PUMILA (BLUME) DAN PENYEDIAAN 
EKSTRAK TERPIAWAI DAN TERFORMULASI NANO UNTUK 
KAJIAN ANTI-OBESITI, ANTI-FIBROID UTERUS DAN ANTI-
KANSER SERVIKS  
 
ABSTRAK 
Labisia pumila Blume, dikenali setempat sebagai Kacip Fatimah, telah lama 
digunakan sebagai tonik wanita dan produk kesihatan. L. pumila juga telah 
digunakan secara tradisional untuk merawat disentri, dismenorea dan gonorea. 
Kajian ini bertujuan untuk memencilkan dan mengenal pasti penanda kimia yang 
berkaitan dengan anti-obesiti, anti-fibroid uterus dan anti-kanser serviks dari ekstrak 
terpiawai L. pumila (LPE), untuk memformulasi dan mencirikan liposom ekstrak 
terpiawai L. pumila (LLP) dan menjalankan kajian kestabilan dipercepat, toksisiti 
dan farmakokinetik ke atas LPE dan LLP. Penilaian aktiviti anti-obesiti secara in 
vitro dan in vivo serta anti-fibroid uterus dan anti-kanser serviks secara in vitro telah 
dicuba. 2,4-di-tert-butilfenol dan labisiakuinon-A telah diasingkan dan dikenal pasti 
menggunakan kaedah NMR, LC-MS/GC-MS, dan FTIR. Pemiawaian LPE 
melibatkan pemprofilan kimia dan analisis kuantitatif menggunakan 5 sebatian 
penanda; asid galik (GA), asid kafeik (CA), rutin (R), 2,4-di-tert-butilfenol (DTBP) 
dan labisiakuinon-A (LA) menggunakan kaedah HPLC yang disahkan. Jumlah 
sebatian penanda dalam LPE ditemui sebanyak 1.03 - 46.36 µg/mg. LPE telah 
berjaya diformulasi sebagai liposom (fomulasi nano) dan dicirikan menggunakan 
penguji saiz zeta, zeta berpotensi, TEM dan FTIR. Saiz zarah purata adalah 171.20 ± 
1.53 nm dengan zeta berpotensi -44.10 ± 1.37, keputusan FTIR menunjukkan 
xxxix 
 
perbezaan ciri-ciri berkaitan dengan kumpulan berfungsi. Dalam kajian kestabilan 
dipercepatkan, LPE dan LLP adalah lebih stabil pada suhu 25°C berbanding suhu 
lain yang dikaji dan jangka hayat dianggarkan (t90) adalah masing-masing 19.40 dan 
22.80 bulan pada 25°C. Hasil kajian anti-obesiti in vitro masing-masing 
menunjukkan perencatan aktiviti lipase pankreas LPE dan LLP sebanyak (di 100 
µg/mL) 21.85 ± 1.39 dan 40.06 ± 2.56%. Orlistat (kawalan positif) pada 100 µg/mL 
menunjukkan perencatan yang lebih tinggi ke atas lipase pankreas in vitro 
berbanding LPE dan LLP. LPE dan LLP mempamerkan aktiviti perencatan tinggi 
pada adiposit 3T3-L1 masing-masing dengan 94.30 ± 0.92 and 98.20 ± 1.49%. Untuk 
aktiviti anti-fibroid uterus secara in vitro, assai MTT telah digunakan dan peratusan 
perencatan untuk LPE adalah 99.01 ± 3.23% dengan IC50 14.24 ± 0.69 µg/mL, 
manakala peratusan perencatan untuk LLP adalah 97.99 ± 2.77% dengan IC50 20.33 
± 1.03 µg/mL. Kawalan positif (doksorubisin, epigallokatekin galat and etoposide) 
mempamerkan kesan anti-proliferasi yang hampir sama dengan LPE dan LLP 
terhadap jalur sel fibroid uterus. Bagi assai kanser serviks in vitro, peratusan 
perencatan untuk LPE adalah 54.69 ± 0.41% dengan IC50 185.00 ± 2.77 µg / mL, 
manakala peratusan perencatan untuk LLP adalah 58.99 ± 0.17% dengan IC50 169.60 
± 2.49 µg/mL. Kawalan positif (5-fluorouracil) menunjukkan aktiviti yang lebih 
tinggi terhadap jalur sel kanser serviks berbanding LPE dan LLP. Untuk aktiviti anti-
angiogenesis, LPE, LLP, DTBP dan LA menunjukkan aktiviti peratusan yang tinggi 
75.41 ± 2.97, 77.36 ± 2.58, 80.16 ± 3.22 dan 83.54 ± 3.43, masing-masing. Dalam 
toksisiti dos akut dan berulang LPE dan LLP menunjukkan bahawa ekstrak selamat 
pada dos yang dipilih (250-5000 mg/kg) dalam tikus Sprague-Dawley. Tiada 
perubahan signifikan diperhatikan dalam ciri-ciri biokimia, hematologi dan histologi 
pada tikus yang dirawat berbanding dengan kumpulan kawalan normal. 
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Farmakokinetik LPE dan LLP telah dijalankan menggunakan kaedah HPLC bagi 
penentuan serentak sebatian penanda plasma selepas pemberian oral dan intravena 
(i.v.). Bioavailabiliti GA, CA, R, DTBP dan LA dalam LPE adalah 6.70 ± 0.21, 3.92 
± 0.15, 3.38 ± 0.14, 3.75 ± 0.12 dan 4.09 ± 0.15%, manakala bagi LLP masing-
masing diperhatikan adalah 9.50 ± 0.29 (P ˂ 0.01) , 5.38 ± 0.23 (P ˂ 0.05), 4.47 ± 
0.22 (P ˂ 0.05), 5.54 ± 0.17 (P ˂ 0.01) dan 5.61 ± 0.23% (P ˂ 0.01). Keputusan ini 
menunjukkan bahawa bioavailabiliti sebatian penanda dalam LLP adalah bertambah 
baik berbanding LPE. Model tikus teraruh diet tinggi lemak selama 45 hari telah 
digunakan dalam assai anti-obesiti LPE dan LLP secara in vivo. Hasil kajian 
menunjukkan pengurangan signifikan dalam indeks jisim badan (P ˂ 0.001), berat 
badan (P ˂ 0.001), pengambilan makanan harian (P ˂ 0.001), jumlah kolesterol (TC) 
(P ˂ 0.001), trigliserida (TG) (P ˂ 0.05), lipoprotein ketumpatan rendah (LDL-C) (P 
˂ 0.001), organ hepar (P ˂ 0.001), dan berat tisu adipos (P ˂ 0.001) dan peningkatan 
lipoprotein berketumpatan tinggi (HDL-C) (P ˂ 0.001) berbanding dengan kumpulan 
kawalan negatif serta mempamerkan ciri histologi hepar normal dalam tikus yang 
dirawat dengan LPE 500 mg/kg dan LLP 500 mg/kg. Kawalan positif (zenoctil dan 
orlistat) didapati kurang atau sama berbanding LPE dan LLP. LPE dan LLP adalah 
selamat pada dos yang terpilih (250-5000 mg/kg), menunjukkan kesan anti-obesiti, 
anti-fibroid uterus dan anti-kanser serviks secara in vitro dan kesan anti-obesiti 
secara in vivo. 
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ISOLATION AND IDENTIFICATION OF CHEMICAL 
MARKERS FROM LABISIA PUMILA (BLUME) AND 
PREPARATION OF STANDARDISED AND 
NANOFORMULATED EXTRACTS FOR ANTI-OBESITY, ANTI-
UTERINE FIBROID AND ANTI-CERVICAL CANCER STUDIES 
 
ABSTRACT 
Labisia pumila Blume, locally known as Kacip Fatimah, has long been used 
as female tonics and health products. L. pumila has also been used traditionally in the 
treatment of dysentery, dysmenorrhoea and gonorrhoea. This study was aimed to 
isolate and identify of chemical markers related to anti-obesity, anti-uterine fibroid 
and anti-cervical cancer from L. pumila standardised extract (LPE), to formulate and 
characterise a liposome of L. pumila standardised extract (LLP) and carry out 
accelerated stability, toxicity and pharmacokinetic studies on LPE and LLP. 
Evaluation of the anti-obesity, anti-uterine fibroid, anti-cervical cancer studies were 
attempted. 2,4-di-tert-butylphenol and labisiaquinone-A were isolated and identified 
using NMR, LC-MS/GC-MS, and FTIR methods. Standardisation of LPE involved 
chemical profiling and quantitative analysis of the 5 selected marker compounds; 
gallic acid (GA), caffeic acid (CA), rutin (R), 2,4-di-tert-butylphenol (DTBP) and 
labisiaquinone-A (LA) using a validated HPLC method. The amount of the selected 
marker compounds in LPE was found to be in the range of 1.03-46.36 µg/mg. LPE 
was successfully formulated as a liposome (nanoformulation) and characterised by 
zetasizer, zeta potential, TEM and FTIR. The average particle size was 171.20 ± 1.53 
nm with zeta potential -44.10 ± 1.37, the FTIR results showed characteristic 
differences in related to functional groups. In accelerated stability study, LPE and 
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LLP were more stable at 25°C compared to other temperatures studied and the 
estimated shelf life (t90) was 19.40 and 22.80 months, respectively, at 25°C. For the 
inhibition effect on pancreatic lipase activity of LPE and LLP at 100 µg/mL, the 
inhibition percentage was at 21.85 ± 1.39 and 40.06 ± 2.56%, respectively. Orlistat 
(positive control) at 100 µg/mL showed better inhibition on pancreatic lipase as 
compared to LPE and LLP. LPE and LLP exhibited high inhibition activity on 3T3-
L1 adipocytes at 94.30 ± 0.92 and 98.20 ± 1.49%, respectively. For the anti-uterine 
fibroid activity, MTT assay was used and the percentage inhibition for LPE was 
99.01 ± 3.23% with IC50 of 14.24 ± 0.69 µg/mL, while the percentage inhibition for 
LLP was 97.99 ± 2.77% with IC50 of 20.33 ± 1.03 µg/mL at 100 µg/mL. The positive 
controls (doxorubicin, epigallocatechin gallate and etoposide) almost showed similar 
anti-proliferative effect on uterine fibroid cell line as compared to LPE and LLP. For 
the anti-cervical cancer assay, the percentage inhibition for LPE was 54.69 ± 0.41% 
with IC50 of 185.00 ± 2.77 µg/mL, while the percentage inhibition for LLP was 58.99 
± 0.17% with IC50 of 169.60 ± 2.49 µg/mL at 200 µg/mL. Positive control (5-
fluorouracil) possessed higher activity on cervical cancer cell line as compared to 
LPE and LLP. For the anti-angiogenesis activity, LPE, LLP, DTBP and LA shows 
high percentage activity 75.41 ± 2.97, 77.36 ± 2.58, 80.16 ± 3.22 and 83.54 ± 3.43, 
respectively. In the acute and repeated dose toxicity of LPE and LLP, the extracts 
were safe at the selected doses (250-5000 mg/kg) in Sprague-Dawley rats. Non-
significant changes were observed in biochemical, haematological and histological 
features in treated rats compared to normal control group. The pharmacokinetics of 
LPE and LLP were performed using HPLC method for the simultaneous plasma 
determination of the selected marker compounds after oral and intravenous (i.v.) 
administration. The observed bioavailability of GA, CA, R, DTBP and LA in LPE 
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was 6.70 ± 0.21, 3.92 ± 0.15, 3.38 ± 0.14, 3.75 ± 0.12 and 4.09 ± 0.15%, while in 
LLP was 9.50 ± 0.29 (P ˂ 0.01) , 5.38 ± 0.23 (P ˂ 0.05), 4.47 ± 0.22 (P ˂ 0.05), 5.54 
± 0.17 (P ˂ 0.01)  and 5.61 ± 0.23% (P ˂ 0.01), respectively. These results indicated 
that the bioavailability of selected marker compounds in LLP was improved 
significantly compared to LPE. A 45 days high-fat diet induced rat model was used 
for the in vivo anti-obesity assay of LPE and LLP. The results of showed significant 
reduction in body mass index (P ˂ 0.001), weight (P ˂ 0.001), daily food intake (P ˂ 
0.001), total cholesterol (TC) (P ˂ 0.001), triglycerides (TG) (P ˂ 0.05), low density 
lipoprotein-cholesterol (LDL-C) (P ˂ 0.001), liver organ (P ˂ 0.001), and adipose 
tissue weight (P ˂ 0.001) and increased high density lipoprotein-cholesterol (HDL-
C) (P ˂ 0.001) as compared to the negative control group and also exhibited normal 
histology features in the liver of the rats treated with LPE 500 mg/kg and LLP 500 
mg/kg. The positive controls (zenoctil and orlistat) were found with less or similar 
activity as compared to LPE and LLP. The selected doses (250-5000 mg/kg) of LPE 
and LLP were found safe, exhibited anti-obesity, anti-uterine fibroid and anti-
cervical cancer effects. 
 
1 CHAPTER ONE: INTRODUCTION 
 
1.1 Background 
Plants have been used as a source of medicine since ancient times up to date. 
Large number of plants are used by world’s population as an important source for 
primary health care conditions (Sahu et al., 2010). Recently, researchers showed high 
interest to search for new medicines from plant source. Many of the medicinal plants 
like Panax ginseng, Camellia sinensis, Allium sativum, Hypericum perforatum, 
Ginkgo biloba and Zingiber officinale have gained popularity for the prevention or 
management of wide number of diseases (Deodhar and Shinde, 2015). In German, 
more than 70% of the physicians prescribe herbs. Medicinal plants are generally 
considered to be safe and effective agents. Therefore, people every year turn to 
herbal medicine because they believe plant remedies are free from undesirable side 
effects (Nasri and Shirzad, 2013). Preparation of new drugs from medicinal plants as 
reliable source has also been considered. Nowadays, researchers more than before 
are dependent on medicinal plants for invention of new drugs with less adverse 
effects (Rafieian-Kopaei, 2011). Majority of the people in the developing countries 
still use traditional indigenous medicines as primary health care. Universally, around 
85% of all medications for primary health care are originated from plants (Abbasi et 
al., 2010). 
 
1.2 Herbs used for the treatment of obesity 
Obesity is the most prevalent health problem affecting all age groups, and 
leads to many complications in the form of diabetes mellitus type 2, chronic heart 
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disease, and stroke (Hasani-Ranjbar et al., 2013). Many herbs are used in the 
traditional medicine for management of obesity such as Zingiber officinale and 
Angelica sinensis. Recently, pharmacological reports on the use of the medicinal 
plants for treatment of obesity are increasing in number. Plant extracts were used 
such as Camellia sinensis, Nigella sativa and Irvingia gabonensi exhibited 
significant reduction in body weight (Hasani-Ranjbar et al., 2013). Medicinal plants 
worth more intention and investigation as an effective treatment for the management 
of obesity. 
 
1.3 Herbs used for the treatment of uterine fibroids 
 Uterine fibroid is a benign tumor in the uterus. Although many women with 
fibroids are not aware of them, the growths may cause symptoms or problems due to 
their size, number, or location. Herbal treatment for uterine fibroids is widely used 
alternatives to surgery, drug treatment or both (Liu et al., 2013). Many herbs were 
used in traditional medicine for management of uterine fibroid such as Cinnamomum 
verum and Zingiber officinale (Bajracharya et al., 2009; Van Andel et al., 2014). 
Currently, pharmacological reports on medicinal plants used for management of 
uterine fibroids are rapidly getting attention. Plant extracts such as Camellia sinensis 
(Zhang et al., 2010a), Allium sativum (Obochi et al., 2009), Panax ginseng (Zhu et 
al., 2015), Cimicifuga racemosa (Xi et al., 2014), Scutellaria barbata (Kim et al., 
2008a) and Euonymus alatus (Lee et al., 2004) showed activity against uterine 
fibroids.  
 
 In addition, formulations from plants like ayurvedic formulations (Dhiman, 
2014) and Nona roguy herbal formulations (Hazlina et al., 2005) also exhibited 
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activity as effective treatment for uterine fibroid. Furthermore, curcumin (Tsuiji et 
al., 2011), berberine (Tang et al., 2009), genistein (Di et al., 2008), isoliquiritigenin 
(Kim et al., 2008c), retinoic acid (Islam et al., 2013) and heparin (Avila et al., 2013) 
are natural compounds from natural origin that have been reported for uterine fibroid 
regression and symptomatic recovery.  
 
1.4 Herbs used for the treatment of cervical cancer 
Cervical cancer is a tumor arising from the cervix. Typically no symptoms are 
seen. Later symptoms may involve pain during sexual intercourse, pelvic pain or 
abnormal vaginal bleeding. Although bleeding after sex may not be serious, it could 
also indicate the presence of cervical cancer (Kumar et al., 2012). Human 
papillomavirus (HPV) infection founds to be responsible for the development of 
more than 90% of cases. Other reasons include oral contraceptives, a weak immune 
system and smoking. Cervical cancer usually develops from precancerous 
changes over 10 to 20 years. About 90% of cervical cancer cases are squamous cell 
carcinomas, and 10% are adenocarcinoma. Cervical cancer can be diagnosed 
by cervical screening followed by a biopsy. Medical imaging is then done to 
determine the extent of the spread of cancer (Tarney and Han, 2014). 
 
Regarding the treatment of cervical cancer using herbs, a famous Chinese 
formulation called “Kung Ching Tang”, contain a mixture of eleven Chinese herbs 
(Achyranthes bidentata, Angelica sinensis, Coix lacryma-jobi, Curcuma zedoaria, 
Cyperus rotundus, Dipsacus asper, Laminaria japonica, Prunela vulgaris, Prunus 
persica, Sparganium stoloniferum, and Vaccaria segetalis) found effective in 
relieving the symptoms and reducing the tumor size (De Moura et al., 2002). 
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Furthermore, root of Hypoxis nyasica investigated against cervical cancer and 
indicated high activity (Bhanot et al., 2011). There is a large number of herbs yet to 
be investigated for treatment of cervical cancer, thus, there is high possibility for 
reaching a stage in the future when cervical cancer will no longer be a threat. 
 
1.5 Problem statement 
 In this study, L. pumila a local plant was selected for studying its anti-obesity, 
anti-uterine fibroid and anti-cervical cancer effects. L. pumila is a medicinal plant 
grown in South East Asia. Recent scientific findings showed that L. pumila have the 
potential for different pharmacological properties such as reducing body weight in 
ovariectomised rats (Fazliana et al., 2009), but no research study was performed on 
anti-obesity effects on high-fat diet induced rat model.  
 
 Although a number of products manufactured from L. pumila are available in 
the market, there is still lack of information in terms of chemical components related 
to anti-obesity, anti-uterine fibroid and anti-cervical cancer effects of L. pumila. 
Furthermore, a new step in development of new generation of standardised herbal 
medicine is preparation of botanical nano-formulation to increase the solubility, 
stability and bioavailability of the active constituents with therapeutic activity. 
 
1.6 Justification of research 
Based on literature review, there is no research work reported on the 
preparation of liposome of L. pumila standardised extract and thereof on the toxicity 
of LPE and LLP. Singh et al. (2009), Mohd Fuad et al. (2007) and Mohd Fuad et al. 
(2005), reported sub-acute, teratogenicity and reproductive toxicity studies of L. 
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pumila water (H2O) extract at 50, 1000 and 800 mg/kg, respectively without any side 
effect. While the present research has been designed to perform the acute toxicity 
and repeated dose toxicity studies of LPE and LLP. Therefore, the present research 
differs from reported studies in terms of parts of plant used, type of extract and 
method of plant extraction.  
 
Furthermore, there is no report on stability, pharmacokinetic and 
bioavailability of L. pumila standardised extract, so, the present research has been 
undertaken to perform accelerated stability, pharmacokinetic and bioavailability on 
LPE and LLP. In addition, there is no reports on anti-obesity, anti-uterine fibroid and 
anti-cervical cancer effects of L. pumila. Therefore, anti-obesity, anti-uterine fibroid 
and anti-cervical cancer effects of L. pumila were studied. This may be helpful for 
herbal industries to prepare and dispense stable and effective herbal products for the 
treatment and management of various illnesses. 
 
L. pumila is reported for reducing body weight in ovariectomised rats 
(Fazliana et al., 2009), but no research study was performed on anti-obesity effects 
on high-fat diet (HFD) induced rat model, anti-uterine fibroid, and anti-cervical 
cancer. Hence, the present research was carried out to investigate the anti-obesity, 
anti-uterine fibroid and anti-cervical cancer effects of LPE and LLP.  
 
1.7 Research hypothesis 
The present research hypothesised that L. pumila standardised extract may be 
formulated as a nano-liposome to improve its stability and bioavailability. 
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Furthermore, this research hypothesised that LPE and LLP may have potential for the 
treatment and management of obesity, uterine fibroid, and cervical cancer. 
 
1.8 General objective 
 This study generally seeks to standardise and assure the quality of L. pumila 
extract by developing new analytical techniques such as HPLC method to quantify 
the chemical markers in L. pumila extract. Furthermore, it seeks to isolate and 
identify the chemical markers related to anti-obesity, anti-uterine fibroid and anti-
cervical cancer effects. Moreover, it seeks to prepare new formulation from 
standardised L. pumila extract using soybean phospholipids in order to improve the 
stability, pharmacokinetics and bioavailability of the active constituents with 
therapeutic activity and to determine the safety of L. pumila extracts thereof. In 
addition, it aims to demonstrate the anti-obesity, anti-uterine fibroid and anti-cervical 
cancer properties of standardised L. pumila extracts. 
 
1.9 Research objectives 
1- To isolate and identify of chemical markers from Labisia pumila. 
2- To carry out quality control assay, standardise, optimise of extraction, prepare 
and characterise liposome of Labisia pumila extract. 
3- To evaluate the stability, toxicity and pharmacokinetics of Labisia pumila 
extracts. 
4- To determine the inhibition effects of Labisia pumila extracts on pancreatic 
lipase, adipocytes, uterine fibroid, cervical cancer cells and angiogenesis.  
5- To determine the in vivo anti-obesity effect of Labisia pumila extracts. 
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1.10 Significance of present research work 
Obesity is increasing at an alarming rate. In 2014 approximately 0.6 billion 
people were observed obese and 1.9 billion were overweight worldwide. In 2013, 
World Health Organisation (WHO) reported that in South-east Asia region, Malaysia 
has become the highest prevalence country for obesity and overweight of 14 and 
42%, respectively. Uterine fibroids occur in 20-25% of the worldwide women 
(McDonald et al., 2011). Cervical cancer is the second most commonly diagnosed 
cancer and third leading cause of cancer death among women in less developed 
countries, nearly 90% of cervical cancer deaths occurred in developing parts of the 
world (Torre et al., 2015). 
 
A study carried out on the effect of L. pumila ovariectomised rats found that 
the plant may break the adipocytes membrane via lipolysis process in adipocytes 
(Kershaw and Flier, 2004; Ayida et al., 2007). Therefore, L. pumila extracts 
evaluated for the anti-obesity effect using high fat diet induced rats. It is believed that 
the plant contains phytoestrogen, which acts as the primary female sexual hormone. 
It is well known that phytoestrogens are essential to protect body against hormonal 
dependent cancers such as uterine and breast (Chua et al., 2012). Therefore, L. 
pumila extracts evaluated for the anti-uterine and anti-cervical cancer effects using 
SK-UT-1(uterine fibroid cells) and HeLa cell lines, respectively. The present 
research introduces the potential of L. pumila extracts as a new herbal product for 
anti-obesity, anti-uterine fibroid and anti-cervical cancer offering a platform for the 
treatment and management to the existing worldwide obesity, uterine fibroid and 
cervical cancer problems. 
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 Figure 1.1 described the flow chart of the research study. Briefly, the plant 
authenticated, washed and dried before optimising the extraction process which 
involved different extraction method, part of the plant and extracting of the plant 
from different locations. After that, the plant analysed for foreign matters, moisture 
content, total ash, acid insoluble ash, extractive values, microbial limit test and heavy 
metals. Then, the plant was estimated for primary and secondary metabolites and 
standardised by using UV-Vis, FTIR and HPLC techniques.  
 
 Later, two marker compounds were isolated and identified using UV-Vis, 
FTIR, NMR, LC-MS/GC-MS and HPLC techniques. For the nano-formulation of the 
plant extract, soybean phospholipid used to formulate the extract and the 
characterisation involved zetasizer, zeta potential, TEM and FTIR methods. Next, 
LPE and LLP were evaluated for accelerated stability study according to 
International Conference on Harmonization (ICH) guidelines at four storage 
conditions for six months.  
 
 After that, LPE and LLP evaluated for the inhibition on pancreatic lipase and 
3T3-L1 adipocytes effects. Furthermore, MTT assay was used to determine the 
activity of LPE and LLP on SK-UT-1 and HeLa cell lines, respectively. In addition, 
LPE and LLP were evaluated for the oral acute and repeated dose toxicity on 
Sprague-Dawley rats according to OECD guidelines. For the pharmacokinetics of 
LPE and LLP, HPLC method was used for the simultaneous plasma determination of 
the selected marker compounds after oral and i.v. administration. Finally, A 45 days 
high-fat diet induced rat model was used for the in vivo anti-obesity assay of LPE 
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and LLP and the body mass index, weight, daily food intake, TC, TG, LDL-C, liver 
organ, adipose tissue weight, HDL-C and liver histology were determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1:1: Flow chart of research study 
Inhibition on pancreatic lipase 
activity  
 Accelerated stability studies of crude 
and nanoformulated extracts 
Inhibition on uterine fibroid and 
angiogenesis studies 
 
Procurement of plant material: Sampling, taxonomic confirmation, drying and 
storage 
 
Quality control of plant sample: Determination of foreign matters, moisture 
content, total ash, acid insoluble ash, extractive values, microbial limit test and 
heavy metals 
Optimisation of extraction: Using different extraction methods such as soxhlation, 
maceration, reflux, sonication and microwave 
Standardisation of the crude extract: Estimation of primary and secondary 
metabolites using UV-Vis, FTIR and HPLC techniques 
 
Isolation and characterisation of 
selected chemical markers using 
UV-Vis, FTIR, NMR, LC-MS/GC-
MS and HPLC techniques 
 
Nano-formulation of the standardised 
extract: Preparation and characterisation 
including particle size, zeta potential, 
TEM-image, UV-Vis, FTIR and aqueous 
solubility 
 
Inhibition on pancreatic lipase, 3T3-
L1, uterine fibroid, cervical cancer and 
angiogenesis studies 
 
Safety studies: Acute oral and repeated 
dose toxicity investigations 
Pharmacokinetics and in vivo anti-
obesity studies 
 
10 
 
2 CHAPTER TWO: LITERATURE REVIEW 
 
2.1 Labisia pumila 
2.1.1 Taxonomic classification 
Family: Primulaceae 
Genus: Labisia 
Species: pumila 
Scientific name: Labisia pumila Blume (Burkill and Haniff, 1930) 
Local name: Kacip Fatimah 
 
2.1.2 Plant description 
L. pumila (synonym: Marantodes pumilum), is the queen of the herbs in 
Malaysia. It is a genus of small woody and leafy plants of the Primulaceae family 
that can widely be found in the tropical forest of South-East Asian countries (Chua et 
al., 2012). Figure 2.1 shows photo of L. pumila var. alata. 
 
Figure  2:1: Photo of L. pumila var. alata (Chua et al., 2012) 
11 
 
To the natives, this plant is also known as Selusuh Fatimah, Rumput Siti 
Fatimah, and Akar Fatimah. Among the various varieties of L. pumila distributed in 
Malaysia, L. pumila var. alata, var. lanceolata and var. pumila are widely found and 
investigated. Differentiation of these varieties from each other can be carried out by 
their leaf and petiole characteristics. L. pumila var. pumila has a marginate petiole 
and ovate leaf blade shape, while var. lanceolata has a long and non-winged petiole, 
and var. alata has a winged petiole and red veins. The var. alata is widely used in 
traditional medicine preparation because it is the most commonly encountered 
variety in Malaysia (Sunarno, 2005; Jamal et al., 2003). 
 
2.1.3 Traditional uses of Labisia pumila 
L. pumila is traditionally used by generations of Malay women by decoction. 
The decoction drink is used to induce and facilitate childbirth, as well as being a post 
partum medication to help contract the birth channel, to regain body strength and to 
tone the abdominal muscles (Chua et al., 2012). Till now, it is taken by local people 
to maintain a healthy female reproductive system, to enhance sexual function, as well 
as to treat menstrual irregularities. Although L. pumila is commonly used by the 
female, however, in Sarawak, Malaysia the males consumed it to maintain and 
increase stamina (Runi, 2000). Other traditional uses of the plant include treatment 
for dysentery, rheumatism, gonorrhoea and excessive gas elimination from the body. 
It was reported that plants from the same genus (Primulaceae) also used to treat 
menstrual disorders and respiratory tract infections. 
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2.1.4 Review of chemical constituents of Labisia pumila 
Several scientific studies on L. pumila described the isolation and 
identification of chemical compounds that contribute to the pharmacological effects. 
Phenolic acids and flavonoids are the most reported compounds (Chua et al., 2011; 
Karimi et al., 2011 and Norhaiza et al., 2009). Chua et al. (2011) reported the 
presence of quercetin, myricetin, kaempferol, catechin, epigallocatechin, salicylic 
acid, syringic acid, vanillic acid, protocatechin acid, coumaric acid, chlorogenic acid, 
gallic acid and caffeic acid. Ardisiacrispin A, ardisicrenoside B, ardisimamilloside H, 
3-O-α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl-(1→4)-α-L-arabinopynansyl 
cyclamiretin A, irisresorcinol, belamcandol B and labisiaquinone A were reported by 
Avula et al. (2011), while 1-O-methyl-6-acetoxy-5-(pentadec-10Z-enyl) resorcinol 
and labisiaquinone B were identified by Al-Mekhlafi et al. (2012).  
 
Fatimahol, 13,28-epoxy-oleanane glycoside and dexyloprimulanin were 
reported in the plant by Ali and Khan (2011). Karimi and Jaafar (2011) identified 
pyrogallol, naringin, daidzein, genistein, apigenin, and rutin from L. pumila. The 
presence of ascorbic acid, β-carotene and anthocyanins were reported by Norhaiza et 
al. (2009). In addition, It has been presented that 5-(pentadec-4′enyl)-resorcinol, 5-
(pentadec-8′-enyl)-resorcinol and 5-(pentadec-10′-enyl)-resorcinol (irisresorcinol) as 
alkenyl resorcinols were found in the plant (Jamal and Houghton, 1999). 
Furthermore, methyl gallate was identified by Hisham et al. (2011). Figure 2.2 
summarise the chemical structures of phytochemicals identified from L. pumila. 
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Figure  2:2: Chemical structures of phytochemicals identified from L. pumila 
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Figure 2.2: Continued. 
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Figure 2.2: Continued 
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Figure 2.2: Continued 
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Figure 2.2: Continued 
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